S pontaneous intracerebral hemorrhage (ICH) accounts for 10% to 15% of all strokes and is one of the leading causes of stroke-related mortality and morbidity worldwide. Patients with ICH are generally at risk of developing stroke-associated pneumonia (SAP) during acute hospitalization. Evidence has shown that SAP not only increases the length of hospital stay (LOS) and medical cost 1,2 but also is an important risk factor of mortality and morbidity after acute stroke. 3, 4 Several risk factors for SAP have been identified, such as older age, 4-12 male sex, 5, 6, 10, 11, 13 current smoking, 12 diabetes mellitus, 6 hypertension, 14 atrial fibrillation, 7, 10, 12 congestive heart failure, 7, 12, 13, 15 chronic obstructive pulmonary disease, 8, [12] [13] [14] preexisting dependency, 8, 12, 13, 16 stroke severity, 5, 6, 8, 12, 17, 18 dysphagia, [8] [9] [10] [11] [12] 14, [18] [19] [20] and blood glucose. 12 Meanwhile, based on these risk factors, a few risk models have been developed for SAP after acute ischemic stroke. [8] [9] [10] [11] [12] Currently, no valid scoring system is available for predicting SAP after ICH in routine clinical practice or clinical trial. We hypothesized that there might be some common grounds for the development of pneumonia after acute ischemic stroke and ICH, and those predictors for SAP after acute ischemic stroke might also be useful for predicting SAP after ICH. For clinical practice, an effective risk-stratification and prognostic model for SAP after ICH would be helpful to identify vulnerable patients, allocate relevant medical resources, and implement tailored preventive strategies. In addition, for clinical trial, it could be used in nonrandomized studies to control for case-mix variation and in controlled studies as a selection criterion.
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September 2014 In the study, we aimed to develop a risk score (ICHassociated pneumonia score, ICH-APS) to predict SAP after ICH using routinely collected variables at presentation. As a result of the fact that hematoma volume is an important prognostic predictor after ICH, 21, 22 we separately developed 2 models with (ICH-APS-B) and without (ICH-APS-A) hematoma volume to test the added value of hematoma volume measure.
Methods

Study Participants
The study was based on the largest stroke registry in China, the China National Stroke Registry (CNSR), 23 which was a nationwide, multicenter, and prospective registry of consecutive patients with acute cerebrovascular events between September 2007 and August 2008. Briefly, hospitals in China are classified into 3 levels: I (community hospitals), II (hospitals that serve several communities), and III (central hospitals for a certain district or city). Level III hospital is usually an academic center and is more medically advanced than level I and II hospitals. Totally, 242 potential sites, including 114 level III, 71 level II, and 57 level I hospitals, from both urban and rural areas were initially identified by soliciting application. The CNSR steering committee evaluated research capability and commitment to the registry of each hospital with preliminary survey. Finally, a total of 132 hospitals, including 100 level III and 32 level II hospitals, were selected, which cover 27 provinces and 4 municipalities across China. Trained research coordinators at each institute reviewed medical records daily to identify, consent, and enroll consecutively Prestroke dependence (mRS ≥3), n (%) 404 (8.1) 256 (8.5) 148 (7.4) 0.15 eligible patients. To be eligible for the study, subjects had to meet the following criteria: (1) age ≥18 years; (2) hospitalized with a primary diagnosis of spontaneous ICH according to the World Health Organization criteria 24 ; (3) ICH confirmed by head computerized tomography; (4) direct admission to hospital from a physician's clinic or emergency department; and (5) written informed consent from patients or their legal representatives. For the study, patients with primary intraventricular hemorrhage were excluded. The scientific use of data registered in the CNSR was approved by the central institutional review board at Tiantan Hospital and local ethical committees at each participating hospital (Appendix).
Data Collection and Variable Definition
In the CNSR network, a standardized case report form was used for data collection. The relevant data were extracted from medical records by trained research coordinators. Data from each case report form were manually checked for completeness, correct coding, and proper application of diagnostic algorithm by a research specialist from an independent contract research organization. For the study, the following candidate variables were analyzed: (1) demographics (age and sex); (2) stroke risk factors: hypertension (history of hypertension or antihypertensive medication use), diabetes mellitus (history of diabetes mellitus or antidiabetic medication use), dyslipidemia (history of dyslipidemia or lipid-lowering medication use), atrial fibrillation (history of atrial fibrillation or documentation of atrial fibrillation on admission), coronary heart disease, history of stroke/transient ischemic attack, current smoking, and excess alcohol consumption (≥2 standard alcohol beverage per day); (3) preexisting comorbidities: congestive heart failure, valvular heart disease, peripheral artery disease, chronic obstructive pulmonary disease, hepatic cirrhosis, peptic ulcer or previous gastrointestinal bleeding, renal failure, arthritis, Alzheimer disease/dementia, and cancer; (4) prestroke dependence (modified Rankin Scale ≥3); (5) preadmission anticoagulation with warfarin; (6) admission Glasgow Coma Scale score; (7) admission National Institutes of Health Stroke Scale (NIHSS) score; (8) admission symptom of dysphagia; (9) admission systolic and diastolic blood pressure (mm Hg); (10) hematoma location (infratentorial or supratentorial ICH); (11) intraventricular extension (with or without intraventricular extension); (12) admission blood glucose (mmol/L); and (13) LOS (days).
The SAP after ICH was diagnosed by treating physician according to the criteria of US Center for Disease Control and Prevention for hospital-acquired pneumonia, 25 on a basis of clinical and laboratory indices of respiratory tract infection (eg, fever, cough, auscultatory respiratory crackles, new purulent sputum, or positive sputum culture), and supported by typical chest x-ray findings. Only hospitalacquired pneumonia was documented, and pneumonia that occurred before stroke was not considered. Data on the development of SAP after ICH were prospectively collected.
Statistical Analysis
The primary objective of the study was to develop a risk score to predict SAP after ICH using routinely collected variables at presentation. We chose not to include variables related to in-hospital management and those not routinely collected, such as mechanical ventilation, 19, 26 prophylactic use of acid-suppressive medications, 27, 28 and swallowing test, 8, 29 despite the fact that these factors might influence the development of SAP after ICH. This model therefore predicts the expected risk of SAP after ICH at presentation.
In the study, eligible patients were randomly divided into derivation (60%) and validation (40%) cohorts. The derivation cohort was used to identify independent predictors and develop scoring system of the ICH-APSs, and the validation cohort was used to verify the established score. In univariable analysis, χ 2 test, independent samples t test, and Mann-Whitney test were used as appropriate. Multivariable logistic regression was performed to determine independent predictors of SAP after ICH in the derivation cohort. Candidate variables were those with biologically plausible link to SAP on the basis of CI indicates confidence interval; COPD, chronic obstructive pulmonary disease; GCS, Glasgow Coma Scale; ICH-APS-A, intracerebral hemorrhage (ICH)-associated pneumonia score (APS) without hematoma volume; ICH-APS-B, ICH-APS with hematoma volume; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; and SAP, stroke-associated pneumonia.
*Multivariable logistic regression for ICH-APS-A adjusted for age, sex, stroke risk factors (hypertension, diabetes mellitus, atrial fibrillation, coronary artery disease, history of stroke/transient ischemic attack [TIA] , current smoking, excess alcohol consumption), comorbidities (congestive heart failure, COPD, peptic ulcer or previous gastrointestinal bleeding, Alzheimer disease/dementia, cancer), prestroke dependence, preadmission anticoagulation, admission GCS score, admission NIHSS score, symptom of dysphagia, ICH location, intraventricular extension, and blood glucose.
†Multivariable logistic regression for ICH-APS-B adjusted for age, sex, stroke risk factors (hypertension, diabetes mellitus, atrial fibrillation, coronary artery disease, history of stroke/TIA, current smoking, excess alcohol consumption), comorbidities (congestive heart failure, COPD, peptic ulcer or previous gastrointestinal bleeding, Alzheimer disease/dementia, cancer), prestroke dependence, preadmission anticoagulation, admission GCS score, admission NIHSS score, symptom of dysphagia, ICH location, intraventricular extension, hematoma volume, and blood glucose.
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September 2014 prior publication and those associated with SAP in univariable analysis (P<0.1). On multivariable analysis, stepwise backward estimation was used to remove nonsignificant variables from the model. To test for collinearity between the covariates of the final multivariable model, the tolerance and variance inflation factor of each covariate were calculated. The β coefficients from the final model were used to generate scoring system of the ICH-APS, as in previous study. 30 The resulting ICH-APSs were then validated by assessing model discrimination and calibration 31 in the validation cohort. Discrimination was assessed by calculating the area under the receiver operating characteristic curve (AUROC). Sensitivity, specificity, positive predictive value, and negative predictive value of the model were calculated at maximum Youden index. Calibration was assessed by performing the Hosmer-Lemeshow goodness-of-fit test and was graphically depicted in the plot of observed versus predicted SAP risk according to 10 deciles of predicted risk.
Because hematoma volume was not documented as part of routine clinical practice, it was not included in the overall model (ICH-APS-A). To test the added value of hematoma volume measure, we separately developed a model (ICH-APS-B) in the subset of patients for whom hematoma volume (measured with ABC/2, where A is the greatest diameter on the largest hemorrhage slice, B is the diameter perpendicular to A, and C is the approximate number of axial slices with hemorrhage multiplied by the slice thickness) 32 was documented using the same approaches described above. The discrimination of the 2 models was compared using the test proposed by DeLong et al. 33 In addition, we used the integrated discrimination index to measure how the model including hematoma volume reclassified patients compared with the model without hematoma volume. The integrated discrimination index can be expressed as (EY 1 −EY 0 )−(EX 1 −EX 0 ), where EY 1 and EY 0 are the mean expected predicted probabilities of SAP in people who had or did not have in model Y (in this case, the model that included hematoma volume) and EX 0 and EX 1 are the mean expected predicted probabilities of SAP in people who had or did not have in model X (in this case, the model that did not include hematoma volume). 34 All tests were 2-tailed, and statistical significance was determined at α level of 0.05. Statistical analysis was performed using SAS 9.1 (SAS Institute, Cary, NC), SPSS 17.0 (SPSS Inc, Chicago, IL), and Medcalc software 12.3 (MedCalc, Ostend, Belgium).
Results
Patient Characteristics
From September 2007 to August 2008, a total of 5136 patients with ICH were enrolled in the CNSR. For the study, 138 (2.7%) patients with primary intraventricular hemorrhage were excluded and 4998 (97.3%) were included in the final analysis ( Figure I in the online-only Data Supplement). The mean age was 61.5 (standard deviation, 13.2), and 62.0% were men. The median LOS was 18 (interquartile range, 11-26) days, and 843 (16.9%) patients developed SAP during acute hospitalization. Compared with patients with LOS >48 hours, those with LOS <48 hours had more severe neurological deficit on admission, lower proportion of SAP after ICH, and significantly higher rate of in-hospital mortality (Table I in the online-only Data Supplement). The eligible patients were randomly divided into derivation (60%; n=2998) and validation (40%; n=2000) cohorts for developing ICH-APS-A, who were matched well for baseline characteristics and SAP after ICH (Table 1) . A total of 783 (15.2%) patients were without documentation of hematoma volume on admission. There was no significant difference in SAP after ICH between patients with and without hematoma volume documentation (Table II in the online-only Data Supplement). As before, patients with hematoma volume documentation (n=4215) were randomly divided into derivation (60%; n=2507) and validation (40%; n=1708) cohorts for developing ICH-APS-B. The clinical characteristics of derivation and validation cohorts for developing ICH-APS-B differed in a few tested variables, such as history of diabetes mellitus, dyslipidemia, atrial fibrillation, and excess alcohol consumption (Table III in 
Development of the ICH-APS-A
The univariable analysis for potential predictors of SAP after ICH in the derivation cohort (n=2998) is shown in Table  IV in the online-only Data Supplement, and the multivariable predictors are listed in Table 2 . Age (P<0.001), current smoking (P=0.007), excess alcohol consumption (P=0.005), chronic obstructive pulmonary disease (P<0.001), prestroke dependence (P=0.001), admission Glasgow Coma Scale score (P=0.02), admission National Institutes of Health Stroke Scale score (P<0.001), dysphagia (P<0.001), ICH location (P=0.02), and intraventricular extension (P=0.02) were identified as predictors of SAP after ICH. The tolerance of covariates in the final model ranged between 0.61 and 0.99; the mean variance inflation factor was 1.16 (range, 1.02-1.96). To derive an integer value for each predictor, the β coefficient of current smoking was used as reference, and the value was rounded to the closest integer (different models were established using β coefficient of other predictors as reference, and the discrimination of these models was similar [data not shown]). The scoring system of the ICH-APS-A is shown in Figure 1 . The median ICH-APS-A score was 4 (range, 0-20) in the derivation cohort. The risk categories were assigned in 4-point increments, and the magnitude of the ICH-APS-A had prognostic implication (Figure 2 ).
The performance (AUROC) of the ICH-APS-A in the overall derivation and validation cohorts was 0.75 (95% confidence interval [CI] , 0.72-0.77) and 0.76 (95% CI, 0.71-0.79), respectively. Interestingly, the ICH-APS-A showed much better discrimination for patients with LOS >48 hours (AUROC, 0.78; 95% CI, 0.75-0.81) than those patients with LOS <48 hours (AUROC, 0.64; 95% CI, 0.55-0.73; Table 3 ). The Hosmer-Lemeshow test was not significant in the overall derivation (P=0.20) and validation (P=0.66) cohorts. The predicted and observed risk of SAP after ICH was in close agreement according to 10 deciles of predicted risk in the overall derivation and validation cohorts ( Figure II 
Development of the ICH-APS-B
Clinical characteristics of study population for developing the ICH-APS-B are shown in Table III in the online-only Data Supplement. The multivariable predictors of SAP after ICH are listed in Table 2 , and the scoring system of ICH-APS-B is shown in Figure 1 . The median ICH-APS-B was 4 (range, 
Comparison of the ICH-APS-A and ICH-APS-B
Discrimination of the ICH-APS-A and ICH-APS-B for SAP after ICH is shown in Table V in the online-only Data Supplement. The difference in discrimination between ICH-APS-A and ICH-APS-B was not statistically significant in the derivation (n=2507), validation (n=1708), and overall (n=4215) cohorts used to develop ICH-APS-B. Two models had similar maximum Youden index and associated positive predictive value and negative predictive value (Table V in 
Discussion
In the study, we developed a risk score for predicting SAP after ICH. We separately developed 2 models (with and without hematoma volume) based on the set of predictors of SAP after ICH. Both models showed good discrimination and calibration in the overall derivation and validation cohorts. Meanwhile, both models demonstrated to be more sensitive for patients with LOS >48 hours. Two models were not significantly different in discrimination and reclassification for SAP after ICH. Several risk factors for SAP have been identified, especially in the setting of acute ischemic stroke. Consistent with these studies, we confirmed that SAP after ICH was significantly associated with older age, current smoking, chronic obstructive pulmonary disease, prestroke dependence, admission Glasgow Coma Scale score, National Institutes of Health Stroke Scale score, and dysphagia. Furthermore, we found that excess alcohol consumption, infratentorial ICH, hematoma volume, and intraventricular extension were associated with increased risk of SAP after ICH. Considerable prior studies have detailed the deleterious effect of alcohol abuse on host immune system, as would result in a higher incidence and severity of infection. 35, 36 Although infratentorial ICH, hematoma volume, and intraventricular extension have been shown to be risk factors for poor outcome after ICH, 21, 22 the underlying molecular mechanisms for increased risk of developing SAP after ICH need to be further investigated.
For a clinical grading scale to become effective and widely used, it must be reliable, accurate, and practicable. For reliability, the ICH-APSs were developed based on a large ICH cohort, which included consecutive patients who were outside clinical trials and were more reflective of real-world clinical practice. For accuracy, the ICH-APSs were proven to be accurate in risk stratification and outcome prediction in both the derivation and validation cohorts, especially for patients with LOS >48 hours. For practicability, the ICH-APSs consist of Figure 3 . The recommended risk-pathophysiology-prevention (R-P-P) model for preventing stroke-associated pneumonia (SAP) and improving prognosis after intracerebral hemorrhage (ICH) in clinical care or clinical research. The recommended R-P-P model for preventing SAP and improving prognosis after ICH could be summarized into 4 steps-step 1 (risk): to stratify the potential risk of developing SAP after ICH by using ICH-APS (either continuous variable or risk categories); step 2 (pathophysiology): to evaluate the potential underlying pathophysiology of SAP after ICH, such as aspiration and stroke-induced immunodepression; step 3 (prevention): to apply tailed preventive strategies based on evaluated risk and pathophysiological mechanisms of SAP after ICH; step 4, to repeat 3 steps mentioned above as necessary when the patient's condition changes.
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Interestingly, both ICH-APS-A and ICH-APS-B showed to be less sensitive for patients with LOS <48 hours. The admission neurological deficit of patients with LOS <48 hours was much more severe than that of patients with LOS >48 hours. Based on prior studies, 5, 6, 8, 12, 17, 18 patients with more severe neurological deficit would have a higher risk of developing SAP after stroke. However, the proportion of SAP after ICH among patients with LOS <48 hours (12.8%) was significantly lower than that of patients with LOS >48 hours (17.2%). Meanwhile, we found that patients with LOS <48 hours had significantly higher rate of in-hospital mortality (47.1%) than those with LOS >48 hours (4.4%; Table I in the online-only Data Supplement). Together, we speculated that patients with shorter LOS (≤48 hours) died or were discharged before the typical onset time for the development of SAP after ICH, and this might be a potential reason for unsatisfactory performance of ICH-APSs among these patients.
It was noteworthy that both ICH-APS-A and ICH-APS-B had higher negative predictive value than positive predictive value for SAP after ICH, which suggested that lower values more consistently predict patients without SAP than higher values predict those developing SAP after ICH. Development of future prognostic models might benefit from attempts to make them more balanced in this regard, with discriminative utility distributed more evenly among higher and lower values.
Prior studies showed that SAP was an important risk factor of mortality and morbidity after stroke; however, systematic review failed to show benefit of early antibiotic prophylaxis for stroke functional outcome or mortality. 37 This might be, at least partially, because of inclusion of patients with too low, too high, or unbalanced risk of developing SAP after stroke in these prior studies. The ICH-APS could be used to identify patients at high risk and to balance the baseline risk of SAP after ICH between different arms in future randomized controlled trials.
Despite advances in medical knowledge, treatment for ICH remains strictly supportive with not many evidence-based interventions currently available. 38 A recent study advocated that prophylactic interventions for poststroke medical complications, especially pneumonia, represent a promising approach to improve the overall neurological outcome after stroke in the long run. 39 Currently, dysphagia screening is a common way used for preventing SAP in clinical practice; however, it cannot directly provide information on potential risk of developing SAP after stroke. In addition, although SAP was thought to occur most often as a result of oropharyngeal dysphagia with secondary aspiration, accumulating evidence indicated that acute stroke could induce significant immunologic changes, such as stroke-induced immunodepression, 40, 41 which was a key facilitating factor for poststroke infection, especially pneumonia. Under this background, as a complement to dysphagia screening, we recommended riskpathophysiology-prevention model for preventing SAP and improving prognosis after ICH in clinical care or clinical research ( Figure 3) . The risk-pathophysiology-prevention model could be summarized into 4 steps-step 1 (risk): to stratify the potential risk of developing SAP using ICH-APS; step 2 (pathophysiology): to evaluate the potential pathophysiology of SAP, such as aspiration and stroke-induced immunodepression; step 3 (prevention): to apply tailed preventive strategies based on evaluated potential risk and pathophysiological mechanisms of SAP; and step 4: to repeat 3 steps mentioned above as necessary when the patient's condition changes. With risk-pathophysiology-prevention model, we look forward to improving ICH outcome by preventing SAP individually, effectively, and economically.
Our study has limitations that deserve comment. First, like all observational studies, we cannot rule out the possibility that additional baseline variable (unmeasured confounders) might have some impact on the risk of SAP after ICH. Second, our study included only hospitalized patients, and those patients who died in emergency department or treated in outpatient clinics were not included. Meanwhile, like most registries, our registry required informed consent, and selection bias was inevitable. 42 Third, because patients in the CNSR network were not routinely screened for swallowing impairments, the rate of dysphagia could be underestimated in the CNSR. Fourth, because we only have information on new-onset SAP during hospitalization without documentation of the exact date, our data do not allow for differentiating whether SAP causes mechanical ventilation or mechanical ventilation causes pneumonia. Prior studies indicated that pneumonia after acute stroke could precede mechanical ventilation, 43 thus making pneumonia a possible risk factor for mechanical ventilation after stroke and not necessarily vice versa. In addition, our primary aim was to develop a predictive model for pneumonia after ICH using variables at presentation. We therefore did not include mechanical ventilation in our model. Finally, both the derivation and validation cohorts originated from the Asian population, and the ICH-APS needs to be further validated in additional populations.
In conclusion, the ICH-APSs are valid clinical grading scales for predicting SAP after ICH at presentation, especially for patients with LOS >48 hours. Additional studies to validate the ICH-APSs in different populations are needed. 
Appendix: The CNSR Investigators
Figure II legend
Plot of observed versus predicted risk of in-hospital SAP after ICH with 95% confidence interval according to 10 deciles of predicted risk. For ICH-APS-A, there was a high correlation between observed and predicted risk in the derivation cohort (A) (n=2998; r=0.988, P<0.001) and validation cohort (B) (n=2000; r=0.998, P<0.001). For ICH-APS-B, the predicted and observed risk were in close agreement according to 10 deciles of predicted risk in the derivation (C) (n=2507; r=0.985, P<0.001) and validation (D) (n=1708; r=0.961, P<0.001) cohorts.
Figure III. Plot of observed versus predicted risk of SAP after ICH in patients with length of hospital stay longer than 48 hours
Figure III legend
Plot of observed versus predicted risk of in-hospital SAP after ICH with 95% confidence interval according to 10 deciles of predicted risk in patients with length of hospital stay longer than 48hours. For ICH-APS-A, there was a high correlation between observed and predicted risk in the derivation cohort (A) (n=2797; r=0.977, P<0.001) and validation cohort (B) (n=1857; r=0.990, P<0.001). For ICH-APS-B, the predicted and observed risk were in close agreement according to 10 deciles of predicted risk in the derivation (C) (n=2353; r=0.989, P<0.001) and validation (D) (n=1590; r=0.995, P<0.001) cohorts.
